However, the pivotal role of DC in cancer immunity has two distinct sides, since DC function can also be exploited by the tumor to inhibit immune effectors in the TME, either via checkpoint ligands like PD-1 or soluble factors like IL-10 [138]. The gene discussed is IL10; the disease is neoplasm.